Table 1.

Patient characteristics

Characteristics	n (%)
No. of patients	81
Age, median (range), yr	39 (21–78)
Male vs. female	41 vs. 40
Stage I–II	23 (28)
Stage III–IV	58 (72)
No. of therapies before CBT, median (range)	4 (1–11)
No. of SCTs prior to CBT	40 (49)
Auto	31
Allo	6
Both (with allo most recent)	3
Disease status prior to CBT
Relapsed (responded for more than 6 mo)	22
Refractory (progressed within 6 mo)	59
DOR to most recent treatment prior to CBT, median (range), days	84 (0–2,953)
No. of CBT infusions, median (range)	8 (1–41)
Best response to CBT
PD	17 (21)
SD	18 (22)
PR	38 (47)
CR	7 (9)
Indeterminate	1 (1)
Reason for discontinuing CBT
PD	53 (65)
Toxicity	13 (16)
Transplant prep	10 (12)
Infection	1
Per protocol	1
CR after adding chemo	1
CR to CBT but PD after discontinuation	2
DOR to post‐CBT therapy, median (range), days	169 (30–1,490)
Time between CBT and subsequent treatment, median (range), days	47 (0–737)
No. of SCTs after CBT	38 (47)
Auto	16
Allo	22

Abbreviations: Allo, allogeneic; Auto, autologous; CBT, checkpoint blockade; CR, complete response; DOR, duration of response; PD, progression of disease; PR, partial response; SCT, stem cell transplant; SD, stable disease.